Giulia Torriani, Evgeniya Trofimenko, Jennifer Mayor, Chiara Fedeli, Hector Moreno, Sébastien Michel, Mathieu Heulot, Nadja Chevalier, Gert Zimmer, Neeta Shrestha, Philippe Plattet, Olivier Engler, Sylvia Rothenberger, Christian Widmann, Stefan Kunz
This is the story of a cell-permeable peptide membrane translocation inhibitor, a potassium channel blocker called TRAM-34 (this is the clotrimazole derivative mentioned in the title) that we found to have anti-arenavirus properties. Amusingly, this turned out to be an off-target effect that had nothing to do with the ability of TRAM-34 to inhibit potassium channels. The identity of the off-target, as today, remains a mystery. To be continued ...